Ann: Quarterly Update and Appendix 4C, page-5

The company has made major strides in the commercialization area in Australia during the past three months and is being seen by all customer groups as an evolutionary development of the current pain assessment tools. The PainChekTM value proposition continues to extend among across the range of healthcare market sectors we are working in.
We are receiving overseas interest including UK, Germany and US and which will support our international market strategy.
In parallel, the development of the next phase Apps remains on track with the adult’s consumer version scheduled for Q2 2018 and children’s App by the end of Q4 2018.

Big year ahead....hold tight.